JP7566766B2 - 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 - Google Patents

抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 Download PDF

Info

Publication number
JP7566766B2
JP7566766B2 JP2021553382A JP2021553382A JP7566766B2 JP 7566766 B2 JP7566766 B2 JP 7566766B2 JP 2021553382 A JP2021553382 A JP 2021553382A JP 2021553382 A JP2021553382 A JP 2021553382A JP 7566766 B2 JP7566766 B2 JP 7566766B2
Authority
JP
Japan
Prior art keywords
antigen
seq
binding fragment
bispecific antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021553382A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020183245A5 (https=
JP2022523442A5 (https=
JP2022523442A (ja
Inventor
ガネーシャン，ラージクマール
グレワル，イクバル，エス．
セプルベダ，マニュエル，アレハンドロ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2022523442A publication Critical patent/JP2022523442A/ja
Publication of JPWO2020183245A5 publication Critical patent/JPWO2020183245A5/ja
Publication of JP2022523442A5 publication Critical patent/JP2022523442A5/ja
Priority to JP2024135000A priority Critical patent/JP2024170426A/ja
Application granted granted Critical
Publication of JP7566766B2 publication Critical patent/JP7566766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021553382A 2019-03-11 2020-03-11 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 Active JP7566766B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135000A JP2024170426A (ja) 2019-03-11 2024-08-13 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962816464P 2019-03-11 2019-03-11
US62/816,464 2019-03-11
PCT/IB2020/000342 WO2020183245A2 (en) 2019-03-11 2020-03-11 ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135000A Division JP2024170426A (ja) 2019-03-11 2024-08-13 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体

Publications (4)

Publication Number Publication Date
JP2022523442A JP2022523442A (ja) 2022-04-22
JPWO2020183245A5 JPWO2020183245A5 (https=) 2023-03-17
JP2022523442A5 JP2022523442A5 (https=) 2023-03-17
JP7566766B2 true JP7566766B2 (ja) 2024-10-15

Family

ID=71670296

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021553382A Active JP7566766B2 (ja) 2019-03-11 2020-03-11 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
JP2024135000A Pending JP2024170426A (ja) 2019-03-11 2024-08-13 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135000A Pending JP2024170426A (ja) 2019-03-11 2024-08-13 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体

Country Status (12)

Country Link
US (2) US12264197B2 (https=)
EP (1) EP3937977A2 (https=)
JP (2) JP7566766B2 (https=)
KR (1) KR20210138033A (https=)
CN (2) CN113874400B (https=)
AU (1) AU2020235475A1 (https=)
BR (1) BR112021017801A2 (https=)
CA (1) CA3132916A1 (https=)
IL (1) IL286147A (https=)
MA (1) MA55305A (https=)
MX (1) MX2021010857A (https=)
WO (1) WO2020183245A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7566766B2 (ja) 2019-03-11 2024-10-15 ヤンセン バイオテツク，インコーポレーテツド 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4192481A4 (en) * 2020-08-10 2024-09-11 Janssen Biotech, Inc. MATERIALS AND METHODS FOR THE PRODUCTION OF VIRUS-SPECIFIC BIOMODIFIED LYMPHOCYTES
US12448449B2 (en) 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
MX2023002948A (es) * 2020-09-11 2023-05-22 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadena beta.
KR20230084507A (ko) * 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 다중-특이적 면역 표적화 분자 및 그의 용도
TWI815194B (zh) * 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20250092134A1 (en) * 2021-11-01 2025-03-20 Janssen Biotech, Inc. Compositions and methods for the modulation of beta chain-mediated immunity
CA3251397A1 (en) * 2022-02-09 2023-08-17 Janssen Biotech, Inc. METHODS AND COMPOSITIONS COMPRISING COMPONENTS FOR BRINGING BISORPOSE VΒ17 T LYMPHOCYTES TO CONTACT WITH BIOMODIFIED VIRUS-SPECIFIC LYMPHOCYTES
WO2024166047A1 (en) * 2023-02-09 2024-08-15 Janssen Biotech, Inc. Anti-v beta 17/anti-cd123 bispecific antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518753A (ja) 2003-02-20 2006-08-17 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
JP2013537418A (ja) 2010-08-17 2013-10-03 シーエスエル、リミテッド ヒト化抗インターロイキン３レセプターα鎖抗体
JP2017529838A (ja) 2014-09-05 2017-10-12 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｄ１２３結合剤及びその使用
JP2018527954A (ja) 2015-09-15 2018-09-27 アダプティミューネ リミテッドＡｄａｐｔｉｍｍｕｎｅ Ｌｉｍｉｔｅｄ Ｔｃｒライブラリ

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6413516B1 (en) 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
FR2681875A1 (fr) 1991-09-26 1993-04-02 Immunotech Sa Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vb17 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
US6084087A (en) 1991-09-27 2000-07-04 New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery DNA encoding conserved T-cell receptor sequences
PT1538206E (pt) 1997-09-16 2010-04-12 Centocor Ortho Biotech Inc Método para a síntese química e construção completa de genes e genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
US20110097339A1 (en) 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
TWI485161B (zh) * 2012-03-02 2015-05-21 中央研究院 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法
WO2014159531A1 (en) 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
KR20170037625A (ko) 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
WO2016073845A1 (en) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
AR104250A1 (es) 2015-04-16 2017-07-05 Eisai R&D Man Co Ltd Anticuerpo anti-notch4 humano
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
WO2018112407A1 (en) * 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
KR20200041834A (ko) 2017-06-01 2020-04-22 젠코어 인코포레이티드 Cd123 및 cd3에 결합하는 이중특이성 항체
CA3081539A1 (en) 2017-11-08 2019-05-16 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2595980B (en) 2019-01-04 2023-06-14 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
JP7566766B2 (ja) 2019-03-11 2024-10-15 ヤンセン バイオテツク，インコーポレーテツド 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
AU2020298324A1 (en) 2019-06-21 2022-01-27 Single Cell Technology, Inc. Anti-TIGIT antibodies
US20210130440A1 (en) 2019-10-03 2021-05-06 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
KR20220147631A (ko) 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
MX2023002948A (es) 2020-09-11 2023-05-22 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadena beta.
US12448449B2 (en) 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
KR20230084507A (ko) 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 다중-특이적 면역 표적화 분자 및 그의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518753A (ja) 2003-02-20 2006-08-17 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
JP2013537418A (ja) 2010-08-17 2013-10-03 シーエスエル、リミテッド ヒト化抗インターロイキン３レセプターα鎖抗体
JP2017529838A (ja) 2014-09-05 2017-10-12 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｄ１２３結合剤及びその使用
JP2018527954A (ja) 2015-09-15 2018-09-27 アダプティミューネ リミテッドＡｄａｐｔｉｍｍｕｎｅ Ｌｉｍｉｔｅｄ Ｔｃｒライブラリ

Also Published As

Publication number Publication date
CN113874400B (zh) 2025-02-07
JP2024170426A (ja) 2024-12-10
BR112021017801A2 (pt) 2022-01-18
WO2020183245A2 (en) 2020-09-17
US20220127359A1 (en) 2022-04-28
IL286147A (en) 2021-10-31
CN119954959A (zh) 2025-05-09
EP3937977A2 (en) 2022-01-19
US20250257132A1 (en) 2025-08-14
WO2020183245A3 (en) 2020-12-03
MA55305A (fr) 2022-01-19
CA3132916A1 (en) 2020-09-17
KR20210138033A (ko) 2021-11-18
MX2021010857A (es) 2021-12-15
AU2020235475A1 (en) 2021-09-30
CN113874400A (zh) 2021-12-31
US12264197B2 (en) 2025-04-01
JP2022523442A (ja) 2022-04-22

Similar Documents

Publication Publication Date Title
JP7566766B2 (ja) 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
JP7686571B2 (ja) Ｔ細胞媒介性免疫を調節するための材料及び方法
AU2022223152A1 (en) Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
RS66901B1 (sr) Anti-cd3 antitela i njihova upotreba
KR20160029128A (ko) 이중특이적 cd3 및 cd19 항원 결합 구조체
TW202231292A (zh) 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
JP2023536818A (ja) Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
TW202210510A (zh) 包含ｃｄ３抗原結合域之蛋白質及其用途
US12448449B2 (en) Immune targeting molecules and uses thereof
CN116390950A (zh) 用于调节δγ链介导的免疫的组合物和方法
CA3219606A1 (en) Heterodimeric fc domain antibodies
JP2024507937A (ja) Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体
KR20240111783A (ko) 면역 반응을 위한 강화된 다중특이성 결합제를 포함하는 조성물
AU2024217296A1 (en) Anti-v beta 17/anti-cd123 bispecific antibodies
RU2831786C2 (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К Vβ17/CD123
CN118742566A (zh) 包含用于免疫应答的增强型多特异性结合剂的组合物
WO2026073840A1 (en) Antibodies that bind to cd3 and uses therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241002

R150 Certificate of patent or registration of utility model

Ref document number: 7566766

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150